MA42264A - Procédé de préparation d'oltipraz - Google Patents
Procédé de préparation d'oltiprazInfo
- Publication number
- MA42264A MA42264A MA042264A MA42264A MA42264A MA 42264 A MA42264 A MA 42264A MA 042264 A MA042264 A MA 042264A MA 42264 A MA42264 A MA 42264A MA 42264 A MA42264 A MA 42264A
- Authority
- MA
- Morocco
- Prior art keywords
- oltipraz
- preparation process
- preparation
- oltipraz preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1891DE2015 | 2015-06-25 | ||
| US14/823,256 US20160376259A1 (en) | 2015-06-25 | 2015-08-11 | Methods for Preparing Oltipraz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42264A true MA42264A (fr) | 2018-05-02 |
Family
ID=57601888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042264A MA42264A (fr) | 2015-06-25 | 2016-06-24 | Procédé de préparation d'oltipraz |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20160376259A1 (fr) |
| EP (1) | EP3313835A4 (fr) |
| JP (1) | JP6773693B2 (fr) |
| KR (1) | KR20180022838A (fr) |
| AU (1) | AU2016283082B2 (fr) |
| CA (1) | CA2989228A1 (fr) |
| MA (1) | MA42264A (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160376259A1 (en) | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for Preparing Oltipraz |
| JP2019531344A (ja) * | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
| AU2017322544B2 (en) * | 2016-09-12 | 2022-06-02 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL171985C (nl) * | 1976-02-10 | 1983-06-16 | Rhone Poulenc Ind | Werkwijze voor het bereiden van preparaten met werking tegen schistosomiasis, de aldus verkregen gevormde preparaten en werkwijze voor het bereiden van 1,2-dithioolverbindingen. |
| AU6462500A (en) * | 1999-07-29 | 2001-02-19 | Patrick T. Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| AU780161B2 (en) | 2000-04-07 | 2005-03-03 | Sang Geon Kim | Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz |
| ATE540586T1 (de) * | 2000-11-20 | 2012-01-15 | Applied Food Sciences Inc | Verfahren zur erhöhung des gehalts an zuträglichen verbindungen nach der verarbeitung in getränken, in denen diese verbindungen natürlich vorkommen |
| KR100491318B1 (ko) * | 2002-11-26 | 2005-05-24 | 씨제이 주식회사 | 올티프라즈(Ｏｌｔｉｐｒａｚ) 제조방법 |
| KR100629771B1 (ko) | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| US20160376259A1 (en) | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for Preparing Oltipraz |
-
2015
- 2015-08-11 US US14/823,256 patent/US20160376259A1/en not_active Abandoned
-
2016
- 2016-06-24 JP JP2017565999A patent/JP6773693B2/ja active Active
- 2016-06-24 MA MA042264A patent/MA42264A/fr unknown
- 2016-06-24 AU AU2016283082A patent/AU2016283082B2/en not_active Ceased
- 2016-06-24 KR KR1020187002139A patent/KR20180022838A/ko not_active Application Discontinuation
- 2016-06-24 CA CA2989228A patent/CA2989228A1/fr not_active Abandoned
- 2016-06-24 EP EP16813869.1A patent/EP3313835A4/fr not_active Withdrawn
-
2018
- 2018-07-20 US US16/041,282 patent/US20190084971A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,915 patent/US20200172522A1/en not_active Abandoned
- 2020-04-21 US US16/854,480 patent/US10968207B2/en active Active
-
2021
- 2021-03-23 US US17/210,049 patent/US20210206752A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200172522A1 (en) | 2020-06-04 |
| EP3313835A4 (fr) | 2019-01-09 |
| US20200247791A1 (en) | 2020-08-06 |
| CA2989228A1 (fr) | 2016-12-29 |
| US20210206752A1 (en) | 2021-07-08 |
| US20160376259A1 (en) | 2016-12-29 |
| US10968207B2 (en) | 2021-04-06 |
| US20190084971A1 (en) | 2019-03-21 |
| KR20180022838A (ko) | 2018-03-06 |
| AU2016283082A1 (en) | 2018-01-18 |
| EP3313835A2 (fr) | 2018-05-02 |
| JP2018520134A (ja) | 2018-07-26 |
| JP6773693B2 (ja) | 2020-10-21 |
| AU2016283082B2 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1248570A1 (zh) | D2o穩定化的藥物製劑 | |
| MA52906A (fr) | Procédé de préparation d'amg 416 | |
| MA54253A (fr) | Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines | |
| ZA201706795B (en) | Process for the preparation of dicycloplatin | |
| MA48798A (fr) | Procédé de production d'ozanimod | |
| MA49472A (fr) | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole | |
| MA42423A (fr) | Procédé de préparation d'un revêtement | |
| MA50517A (fr) | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole | |
| FR3038312B1 (fr) | Procede de preparation de polyols | |
| FR3019967B1 (fr) | Procede d'ostreiculture ameliore | |
| MA42264A (fr) | Procédé de préparation d'oltipraz | |
| PL3253772T3 (pl) | Sposób otrzymywania diosminy | |
| HK1246146A1 (zh) | 用於治療真菌病的藥物組合物 | |
| IL254578A0 (en) | Abscisic acid (s)-2' vinyl derivatives | |
| GB2561089B (en) | Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one | |
| GB2564185B (en) | Process for the preparation of derivatives of benzodioxole | |
| MA42048A (fr) | Dérivés d'aminoesters | |
| MA49555A (fr) | Procédé amélioré de préparation d'imetelstat | |
| FR3024729B1 (fr) | Procede de preparation du trioxane | |
| FR3011839B1 (fr) | Procede de preparation de derives d'acetamidophenyle | |
| HK1245267A1 (zh) | 用於製備噻吩並-吲哚衍生物的不對稱方法 | |
| MA40446A (fr) | Procédé de préparation de formulations pour inhalation | |
| ITUB20153121A1 (it) | Apparato per l'ozonoterapia | |
| MA45184A (fr) | Procédé de préparation de l'éluxadoline . | |
| FR3018075B1 (fr) | Procede de preparation de derives d'acide 2,4-diamino-3-hydroxybutyrique |